In this issue, guest editors bring their considerable expertise to this important topic.
Key Features
Provides in-depth reviews on the latest updates in the field, providing actionable insights for clinical practice. Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create these timely topic-based reviews.
Author Information
Edited by Deepak L. Bhatt, MD, MPH, FACC, FAHA, FESC, MSCAI, Director of Mount Sinai Heart, Dr. Valentin Fuster Professor of Cardiovascular Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, United States and Ragavendra R. Baliga, MD, MBA, FACP, FRCP, FACC, Inaugural Director, Cardio-Oncology Center of Excellence Professor of Internal Medicine The Ohio State University Wexner Medical Center
Edited by Deepak L. Bhatt, MD, MPH, FACC, FAHA, FESC, MSCAI, Director of Mount Sinai Heart, Dr. Valentin Fuster Professor of Cardiovascular Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, United States and Ragavendra R. Baliga, MD, MBA, FACP, FRCP, FACC, Inaugural Director, Cardio-Oncology Center of Excellence Professor of Internal Medicine The Ohio State University Wexner Medical Center
Glucose-Lowering and Metabolic Effects of SGLT2 Inhibitors Renoprotective Effects of SGLT2 Inhibitors SGLT2 Inhibitors in Type 2 Diabetes Mellitus SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: A Paradigm Shift Toward Dual Cardio-Renal Protection SGLT2 Inhibitors and Heart Failure with Preserved Ejection Fraction SGLT2 Inhibitors in Heart Failure: Early Initiation to Achieve Rapid Clinical Benefits Sodium-Glucose Cotransporter-2 Inhibitors: Impact on Atherosclerosis and Atherosclerotic Cardiovascular Disease Events SGLT2 Inhibitors and Peripheral Vascular Events: A Review of the Literature Sodium-glucose Cotransporter 2 Inhibitors and Nonalcoholic Fatty Liver Disease SGLT2 Inhibitors and Safety in Older Patients Sodium Glucose Cotransporter 2 Inhibitors, Amputation Risk, and Fracture Risk
https://www.asia.elsevierhealth.com/sglt-2-inhibitors-an-issue-of-heart-failure-clinics-9780323960465.html305003SGLT-2 Inhibitors, An Issue of Heart Failure Clinicshttps://www.asia.elsevierhealth.com/media/catalog/product/9/7/9780323960465_4.jpg66.7488.99USDInStock/Medicine & Surgery/Cardiology/Medicine/Cardiology/Clinics/Clinics/Clinics/Medicine/Cardiology/Japan Titles44312125054569505466643887255255041525985052631601418269243350884886536505455351451205259833In this issue, guest editors bring their considerable expertise to this important topic. In this issue, guest editors bring their considerable expertise to this important topic.00add-to-cart97803239604652022ProfessionalEdited by Deepak L. Bhatt, MD, MPH, FACC, FAHA, FESC, MSCAI and Ragavendra R. Baliga, MD, MBA, FACP, FRCP, FACC20221Book178w x 254h (7.00" x 10.00")Elsevier240Oct 11, 2022IN STOCKEdited by <STRONG>Deepak L. Bhatt</STRONG>, MD, MPH, FACC, FAHA, FESC, MSCAI, Director of Mount Sinai Heart, Dr. Valentin Fuster Professor of Cardiovascular Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, United States and <STRONG>Ragavendra R. Baliga</STRONG>, MD, MBA, FACP, FRCP, FACC, Inaugural Director, Cardio-Oncology Center of Excellence Professor of Internal Medicine The Ohio State University Wexner Medical CenterClinicsClinicsThe Clinics: Internal MedicineUnited StatesNoNoNoNoPlease SelectPlease SelectPlease Select
